MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%

MAIA Biotechnology completed enrollment for Part C of its Phase 2 THIO-101 trial and reported 65 patients enrolled in its Phase 3 THIO-104 trial, targeting 100 by 2026. Interim analysis is planned for 2027, according to the company.

MAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.

MAIA Biotechnology expanded its Phase 3 THIO-104 trial for Ateganosine, an investigational lung cancer treatment, into Spain and Portugal. The study aims to enroll 100 patients by 2026, with an interim analysis planned for 2027. MAIA's stock has traded between $0.87 and $3.19 in the past year, closing at $1.32 on Wednesday.

DataMEDS AI (MEDS) rose 295.53% after acquiring Helomics for $1.5M, expanding into precision oncology. Tempest Therapeutics (TPST) gained 58.86% with a CAR-T licensing deal. NeurAxis (NRXS) increased 22.63% on expanded insurance coverage for its PENFS therapy. MAIA Biotechnology (MAIA) rose 5.22% after dosing the first U.S. patient in its THIO-101 trial.

MAIA Biotechnology (MAIA) dosed the first U.S. patient in its Phase 2 THIO-101 trial for advanced non-small cell lung cancer, following FDA clearance. The trial, funded by a $2.3M NIH grant, evaluates Ateganosine, a telomere-targeting therapy with FDA Fast Track designation. MAIA's stock is up 4% at $1.39.

MAIA Biotechnology, Inc. (NYSE American: MAIA) dosed the first U.S. patient in its Phase 2 THIO-101 trial for ateganosine in third-line non-small cell lung cancer (NSCLC). The trial is funded by a $2.3 million NIH grant. Ateganosine has FDA Fast Track designation and showed promising overall survival data in prior trials.